Veracyte Inc
Abrir
SetorSaúde
48.29 2.16
Visão Geral
Variação de preço das ações
24h
Mín
46.6
Máximo
47.91
Rendimento | -20M 29M |
|---|---|
Vendas | -1.6M 139M |
P/E Médio do Setor | 45.019 49.052 |
EPS | 0.52 |
Margem de lucro | 20.642 |
Funcionários | 755 |
EBITDA | -17M 29M |
Recomendações | Comprar |
|---|---|
Previsão para 12 meses | +0.51% upside |
Próximos Ganhos | 5 de ago. de 2026 |
|---|
Capitalização de Mercado | 1.1B 3.8B |
|---|---|
Abertura anterior | 46.13 |
Fecho anterior | 48.29 |
Sentimento de Notícias
By Acuity
50%
50%
146 / 342 Ranking em Healthcare
Veracyte Inc Gráfico
O desempenho passado não é um indicador confiável de resultados futuros.
Sobre Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.